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The dissolution process is considered an important in vitro tool to evaluate product quality and drug 
release behavior. Single dissolution methods for the analysis of combined dosage forms are preferred to 
simplify quality control testing. The objective of the present work was to develop and validate a single 
dissolution test for a telmisartan (TEL) and amlodipine besylate (AML) combined tablet dosage form. 
The sink conditions, stability and specificity of both drugs in different dissolution media were tested 
to choose a discriminatory dissolution method, which uses an USP type-II apparatus with a paddle 
rotating at 75 rpm, with 900 mL of simulated gastric fluid (SGF without enzymes) as the dissolution 
medium. This dissolution methodology provided good dissolution profiles for both TEL and AML and 
was able to discriminate changes in the composition and manufacturing process. To quantify both drugs 
simultaneously, a synchronous first derivative spectrofluorimetric method was developed and validated. 
Drug release was analyzed by a fluorimetric method at 458 nm and 675 nm for AML and TEL, respectively. 
The dissolution method was validated as per ICH guidance.
Uniterms: Combined dosage forms/quality control. Dissolution test/combined dosage forms. Telmisartan. 
Amlodipine besylate. Spectrofluorimetry/quantification analysis. 
O processo de dissolução é considerado como uma importante ferramenta in vitro para avaliar a qualidade 
do produto e o comportamento de liberação do fármaco. Prefere-se um ensaio único de dissolução 
para formas farmacêuticas contendo associação de fármacos pela simplificação dos testes de controle 
de qualidade. O objetivo do presente trabalho foi desenvolver e validar um teste de dissolução único 
para forma farmacêutica comprimidos contendo telmisartana (TEL) e besilato de anlodipino (AML) 
associados. Condições “sink”, estabilidade e especificidade de ambos os fármacos nos diferentes meios 
de dissolução foram avaliadas para selecionar um método de dissolução discriminatório, que utiliza um 
aparato do tipo II da USP, com pás girando a 75 rpm e 900 mL de fluido gástrico simulado (SGF sem 
enzima) como o meio de dissolução. Estas condições proporcionaram bons perfis de dissolução para 
ambos, TEL e AML, sendo capaz de discriminar as mudanças na composição e processo de fabricação. 
Para quantificar os dois fármacos simultaneamente, um método de fluorescência derivada sincronizado 
foi desenvolvido e validado. A quantidade de fármaco liberado foi analisada pelo método fluorimétrico 
em 458 e 675 nm para a AML e TEL, respectivamente. O método de dissolução foi validado de acordo 
com a orientação da ICH.
Unitermos: Forma farmacêutica com associação/controle de qualidade. Teste de dissolução/forma 
farmacêutica com associação. Telmisartana. Besilato de anlodipino. Espectrofluorimetria/análise 
quantitativa.
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INTRODUCTION
Drug dissolution testing an important analytical 
technique to evaluate product quality, to assess drug release 
behavior and to discriminate changes in the formulation 
and manufacturing process (Kulkarni et al., 2012). The 
strategy to determine the solubility and permeability 
properties of drugs uses a biopharmaceutical classification 
system to classify drugs into four basic groups (Amidon 
et al., 1995). The development of a dissolution method 
for a drug product with limited water solubility and 
combinations of drugs has been a challenge for both the 
pharmaceutical industry and regulatory agencies (Soni et 
al., 2008; Dressman et al., 1998; Oliveira et al., 2009). 
Currently, there is increased demand for biorelevant 
dissolution media, which have the ability to discriminate 
changes in the formulation and manufacturing process 
(He et al., 2004; Panikumar et al., 2012; Menegola et 
al., 2007). In vitro dissolution media is formulated to be 
biorelevant, as it should be able to serve as a surrogate of 
the in vivo environment. In vitro dissolution media are 
made biorelevant by adding various levels of bio-salts, 
lecithin and fatty acids (Galia et al., 1998). A single 
dissolution method for the analysis of multiple API active 
components in combinations present in a dosage form is 
preferred to simplify quality control testing procedures 
(Vignaduzzo et al., 2010; Huang et al., 2011; Panikumar 
et al., 2013; Zongyun et al., 2011).
Telmisartan (TEL) (Figure 1A), chemically 
known as 4′-[(1,4′-dimethyl-l-2′-propyl[2,6′-bi-1H-
benzimidazol]-1′yl)methyl]-[1,1′-biphenyl]-2–carboxylic 
acid, is a angiotensin–II (AT1) receptor antagonist used in 
the treatment of hypertension and myocardial infarction. 
Amlodipine besylate (AML) (Figure 1B), chemically 
known as 3-ethyl-5-methyl 2-(2-amino ethoxy methyl)-
4-(2-chloro phenyl)-1,4-dihydro-6-methyl pyridine-3,5-
dicarboxylate benzene sulfonate, is a calcium channel 
blocker used in the treatment of hypertension and angina 
pectoris (Anthony , David, Brian, 2004). TEL and AML 
have been formulated in a fixed-dose combination used in 
the treatment of hypertension. To the best of our knowledge, 
no single dissolution test has been reported for TEL and 
AML in a combined tablet dosage form. Therefore, the 
objective of the present investigation was to develop and 
validate a single discriminating dissolution test method 
for TEL and AML in a combined tablet dosage form. A 
literature survey revealed that a few analytical methods 
are available for the simultaneous quantification of TEL 
and AML by spectrophotometry (Pratap et al., 2012) and 
high performance liquid chromatography (Mhaske et al., 
2012; Kottai et al., 2010). Chromatographic methods 
are complex, as they require expensive instrument setup 
and skilled operators (Basavaiah, Raghu, Vinay, 2012). 
Spectrophotometry methods are unsuitable for the 
evaluation of drugs in multi-component analysis because 
of the lack of specificity (Mark, Workman Jr., 2003).
Spectrofluorimetry has assumed a major role in drug 
analysis because of its greater sensitivity and selectivity 
than absorption spectrophotometry (Gomez-Hens, 1991). 
The synchronous first derivative spectrofluorimetry 
technique is superior in terms of sensitivity, spectral 
discrimination, and provides more reliable identification 
of chemical species in multi-component analysis without 
interference from formulation excipients and components 
of the dissolution media (Andrade et al., 2010; Belal 
et al., 2011; Ei-wassef et al., 2009). Therefore, we 
developed and validated a simple synchronous first 
derivative spectrofluorimetric method for the simultaneous 
quantification of TEL and AML in dissolution samples.
MATERIAL AND METHODS
Material
All chemicals and reagents were of analytical grade. 
Telmisartan (TEL) and amlodipine besylate were gift 
samples from Dr. Reddy’s Laboratories Ltd, Hyderabad. 
Telsartan-AM and Sartel-AM formulations (TEL 40 mg 
and AML 5 mg) were purchased from local pharmacies. 
Hydrochloric acid, ortho-phosphoric acid, potassium 
dihydrogen orthophosphate, sodium hydroxide and 
sodium chloride were purchased from SD Fine Chemicals 
Ltd, Mumbai, India; sodium lauryl sulfate (SLS), Tween 
80, cetrimide, lecithin and sodium taurocholate were 
purchased from Himedia Ltd, Mumbai, India.
Instrumentation
The fluorescence spectra and measurements 
were recorded using a Shimadzu (Japan) RF-5301 PC 
FIGURE 1- Chemical structure of telmisartan (A) and 
amlodipine besylate (B).
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spectrofluorophotometer, equipped with a 150 W Xenon 
arc lamp. A 1 cm quartz cell was used, connected to 
RFPC software. The instrument was operated both at 
low and high sensitivity with the excitation and emission 
slit width set at 5 nm. A dissolution apparatus (Electro 
lab TDT-08L), analytical balance (Shimadzu AUX 220, 
Japan), pH meter (Elico), tablet compression machine 
(Lab Press, CIP Machineries, Ahmedabad, India) and 
hardness tester (Secor, Hyderabad, India) were used for 
the study.
Analytical method
Standard solutions of TEL and AML were diluted 
appropriately with 1 molar (M) hydrochloric acid 
(HCl) to obtain solutions containing TEL (4 µg/mL) 
and AML (4 µg/mL). The fluorescence spectra of these 
diluted solutions were scanned in the spectral range of 
350 to 800 nm. The normal spectra of TEL and AML 
were transformed to corresponding synchronous first 
derivative spectra in the range of 350 to 800 nm and 
overlapped. The first derivative spectrum of TEL had 
zero intensity at 458 nm, whereas AML gave a significant 
derivative response. The derivative spectrum of AML had 
zero intensity at 675 nm, whereas TEL gave a significant 
derivative response. Therefore, 458.0 nm was selected 
for the estimation of AML and 675 nm was selected for 
the estimation of TEL in the co-formulation and in vitro 
dissolution studies.
Dissolution test conditions
Dissolution testing of TEL (40 mg) and AML (5 
mg) bulk drug-filled capsules (12 units) was performed 
using a paddle-type USP tablet dissolution apparatus, in 
900 mL of various buffers, such as 0.1 M HCl, acetate 
buffer (pH 2.7 and 4.7), phosphate buffer (pH 3.6/5.6/6.8 
and 7.4) and like simulated gastric fluid without enzymes 
(SGF); modified fasted and fed state intestinal fluids 
(MFaSSIF and MFeSSIF) and blank fasted and fed 
state intestinal fluids (FaSSIF and FeSSIF) at 50 rpm 
and at 37±0.5 °C for 60 min. Aliquots of 5.0 mL were 
withdrawn at 5 min interval up to 60 min, and replaced 
with an equal volume of fresh medium to maintain sink 
conditions. At the end of the test, the withdrawn samples 
were filtered, diluted with 1 M HCl and quantified by the 
developed and validated spectrofluorimetric method. The 
dissolution studies were conducted three times using four 
capsules in each of the media (12 units). The amount 
of dissolved drugs was computed from the respective 
calibration curves and then plotted against time. The 
media in which highest drug release occurred for the 
TEL and AML bulk drugs was the medium chosen for 
the in vitro dissolution studies of the tablet dosage form 
(Telsartan-AM and Sartal-AM).
Validation of the dissolution method
The method was validated by the analysis of 
specificity, linearity, accuracy and precision as per ICH 
guidelines (2005).
The specificity of the proposed method was 
evaluated through the analysis of a placebo solution, which 
was prepared with the common excipients (lactose, starch, 
microcrystalline cellulose, magnesium stearate, titanium 
dioxide and talc) of the pharmaceutical formulation. Thus, 
the mixture of inert components was prepared in their usual 
concentrations employed in tablets (concentrations were 
determined based on the Handbook of Pharmaceutical 
Excipients and calculated for the medium weight of the 
contents) (Raymond, Paul, Sian, 2007). The developed 
method was applied in order to check if any component 
of the formulation could generate a response or generate 
an emission band similar to the drugs.
Linearity was determined by constructing the plot 
between analyte intensity vs. concentration to calculate 
the regression line for standard dilutions of 4-14 (TEL) 
and 1-6 µg/mL (AML) using the linear least squares 
methodology.
The precision of the method was determined by 
intra-day precision and inter-day precision variations as 
per ICH guidelines. The intra-day precision and inter-day 
precision were assessed after subjecting six tablets to the 
dissolution test conditions, on the same day and on three 
different days respectively. The % RSD was calculated.
The accuracy was carried out by adding known 
amount of standard drug at 80, 100 and 120% of the 
nominal assay of TEL and AML to the placebo sample in 
the dissolution media and then subjected to the proposed 
dissolution method. The experiment was conducted in 
triplicate. The percentage recovery and percentage relative 
standard deviation (%RSD) were calculated for each 
concentration.
Stability determination
Sample solutions were prepared in the optimized 
dissolution media and at the same dissolution test 
conditions. Aliquot samples were collected initially and 
at 24 h intervals for 2 days and analyzed by the proposed 
analytical method. The drug concentrations were 
compared after 0, 24 and 48 h.
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RESULTS AND DISCUSSION
Development of dissolution method
The selection of a dissolution test method was based 
on screening studies using a USP type II apparatus at a 
paddle speed of 50/75 rpm. The selection of a dissolution 
medium to provide adequate solubility and stability of 
both TEL and AML was critical for the selected dissolution 
method. The log P values of TEL and AML were 6.66 and 
3.0, respectively, indicating the poor water solubility and 
lipophilic character of both drugs. TEL is soluble in strong 
acid and basic media, but strong basic media are not suitable 
as dissolution media because of the gastrointestinal pH 
range of 1.0-7.4. AML solubility was similar in all buffered 
media (pH 1.2-7.5). The screening results showed that the 
dissolution rates of both bulk drugs were higher in simulated 
gastric fluid (SGF) media (pH 1.2) than other media (Table 
I), due to the interaction between lone pairs of electrons on 
nitrogen atoms and the ionizable groups present in TEL 
and AML with NaCl, HCl molecules present in SGF media 
(prepared as per USP-2007, without enzymes, consisting of 
2 gm sodium chloride, 0.2M hydrochloric acid to adjust pH 
to 1.2 and volume make upto 1000 mL). Thus, this media 
was useful for the quality control testing of both drugs in 
tablets. The pH of the dissolution medium was 1.2, i.e. 
within the range of gastrointestinal tract pH levels, and 
therefore mimicked the gastrointestinal tract environment 
(biorelevant). This assay was designed to provide 
information for pharmaceutical researchers involved in the 
development of new biorelevant dissolution media and in 
predicting the in vivo performance of poorly soluble drugs. 
Therefore, the selected dissolution test conditions were: 
USP type II apparatus at a paddle speed of 75 rpm in 900 mL 
of simulated gastric fluid (pH 1.2).
In vitro dissolution studies from tablet dosage 
forms
Dissolution studies on Telsartan-AM and Sartel-AM 
tablets were performed under the optimized dissolution 
test conditions. These results are shown in Figures 2 and 
3, and reveal that more than 90% of both TEL and AML 
were released from the two products.
Stability studies
Both TEL and AML were found to be stable under 
dissolution test conditions and the measured derivative 
absorbance of the initial time and after 24 and 48 h was 
similar. There was no evidence of degradation of the drugs 
under the dissolution test conditions, indicating that the 
solutions were stable for more than 48 h.
Discriminatory power of the dissolution method
The discriminatory power of the dissolution method 
was determined by manufacturing tablets under different 
TABLE I - Screening study results for dissolution of TEL (40 mg) 
and AML (5 mg) bulk drug using a USP type II apparatus at 
50 rpm, temperature 37 ºC±0.5 for 60 min
Dissolution media
% Drug release  
Mean± RSD (n = 12) 
TEL AML
0.1 N Hydrochloric acid 73.57±0.30 100.50±1.92
Acetate buffer, pH 2.7 7.11±0.28 94.88±0.35
Acetate buffer, pH 3.6 12.03±1.30 97.37±4.66
Acetate buffer pH 4.7 14.91±2.41 100.98±0.03
Phosphate buffer, pH 5.6 13.81±1.22 98.86±2.05
Phosphate buffer, pH 6.8 19.73±0.62 98.88±4.03
Phosphate buffer, pH 7.4 9.27±0.30 71.89±6.18
SGF (simulated gastric fluid 
without enzymes)
79.17±2.12 98.18±5.44
BFaSSIF (Blank fasted state 
simulated intestinal fluid)
11.89±0.825 95.42±2.58
BFeSSIF (Blank fed state 
simulated intestinal fluid)
5.08±0.445 98.42±2.88
MFaSSIF (Modified fasted 
state simulated intestinal fluid)
11.48±0.45 99.42±2.59
MFeSSIF (Modified fed state 
simulated intestinal fluid)
5.17±0.33 100.0±1.10
Telsartan-AM Tablets
50 rpm, SGF media 86.66±0.29 99.28±0.01
75 rpm, SGF media 96.86±1.22 98.28±0.02
Sartel-AM Tablets
50 rpm, SGF media 88.03±1.20 99.05±2.03
75 rpm, SGF media 93.81±1.59 99.01±2.05
FIGURE 2 – In vitro dissolution profile of Telsartan-AM tablets 
in SGF media at 75 rpm (n = 12).
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TABLE II - Data obtained from stability studies
% Amount of drug found
Drug initial time after 24 h after 48 h
TEL 98.01 98.05 99.05
AML 99.06 100 99.06
FIGURE 3- In vitro dissolution profile of Sartel-AM tablets in 
SGF media at 75 rpm (n=12).
FIGURE 4 - Comparison of dissolution profiles of TEL/AML tablets manufactured with different hardness.(A) Profile for TEL 
and (B) for AML.
FIGURE 5- Comparison of dissolution profiles of TEL/AML tablets manufactured with and without a disintegrant.(A) Profile for 
TEL and (B) for AML.
conditions and checking the dissolution behavior in the 
presence of the proposed dissolution test conditions. The 
effect of tablet hardness (5 kg/cm2 vs. 8 kg/cm2 ) and the 
disintegrant (with disintegrant vs. without disintegrant) are 
shown in Figures 4 and 5, revealing that dissolution rate of 
both drugs was slightly faster for tablets with less hardness 
and with a disintegrant. Therefore, this dissolution method 
has the ability to discriminate changes in the composition 
and manufacturing process. The dissolution profile data 
were also compared mathematically using the similarity 
fit factor (f2).
If f2 is less than 50, then two dissolution profiles 
are considered dissimilar. The similarity increases as the 
f2 value increases above 50 and approaches 100 (FDA 
1997). The similarity factor f2 was calculated from the 
dissolution profile, using five points for telmisartan and 
three points for amlodipine besylate. Among these, one 
point was found to indicate more 85% of drug release. 
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Table III lists the f2 values used for the comparison of the 
dissolution profiles for each of the process parameters 
evaluated. These results confirm that the dissolution test 
procedure has discriminating power regarding variation in 
the composition and manufacturing process.
Method validation
Specificity
The synchronous fluorescence derivative spectra of 
the placebo, TEL and AML in the dissolution medium are 
shown in Figure 6. Perusal of the figure shows that there 
was no interference from the excipients in the tablets and 
dissolution medium with the derivative response of either 
of the drugs (TEL and AML) at their respective analytical 
wavelengths. Therefore, the proposed method is specific.
Linearity
The linearity was evaluated by the least square 
regression method. The responses for TEL at 675 nm 
were found to be linear in the concentration range of 4-14 
µg/mL, with a correlation coefficient (r) value of 0.997. 
Similarly, the responses for AML at 458 nm were linear in 
the concentration range of 1-6 µg/mL, with a correlation 
coefficient (r) value of 0.999. The results indicate a good 
linear relationship between the derivative response and 
concentration. Linearity plots are shown in Figure 7.
Precision
The percent relative standard deviation values for 
intra and inter day precision studies were found to be less 
than 2 and there was no significant difference observed 
between the intra- and inter-day values, which indicates 
that the proposed method was reproducible and precise. 
The results are reported in Table IV.
Accuracy
Accuracy shows the agreement between the standard 
value and the observed value. The accuracy results of 
the proposed dissolution method are reported in Table 
V. Percent recovery was from 97.0-99.0% and percent 
relative standard values were less than 2; this signifies 
that the dissolution method is accurate for its intended use.
CONCLUSION
The discriminating and dissolution test developed 
and validated for TEL/AML tablets was considered 
satisfactory. The best conditions optimized for dissolution 
testing for TEL/AML tablets were: 900 mL of simulated 
gastric fluid (SGF without enzymes), a paddle-type 
apparatus, stirring speed of 75 rpm, a temperature of 37 
ºC±0.5 and collection time of 60 min. The dissolution 
studies for TEL and AML combination tablets in the 
proposed dissolution media were found to be better, 
because of their discriminating power, utility as a surrogate 
of the gastrointestinal tract environment (biologically 
relevant). In addition, these studies provide information for 
pharmaceutical researchers involved in the development 
of new biorelevant dissolution media and predicting 
the in vivo performance of poorly soluble drugs. The 
TABLE III - Similarity factor (f2) for dissolution profiles of tablets 
with different parameters
f2 Value
Process 
parameter
Tablets with 
hardness of 5 kg/
cm2 vs. 8 kg/cm2
Tablets containing 
disintegrant vs. no 
disintegrant
TEL 44.47 63.14
AML 46.14 49.21
FIGURE 6 - Synchronous first order derivative spectrum of 
placebo (A), blank dissolution medium (B), AML (C) and TEL 
(D).
FIGURE 7 - First derivative synchronous linearity spectrum of 
amlodipine besylate (AML) and telmisartan (TEL).
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TABLE IV - Precision data for the proposed dissolution method
Product 
TEL AML
Intra-day (%) Inter-day (%) Intra-day (%) Inter-day (%) 
Mean±SD %RSD Mean±SD %RSD Mean±SD %RSD Mean±SD %RSD 
Telsartan-AM 96.86±1.07 1.11 97.28±0.78 0.80 98.28±0.11 0.11 99.98±0.99 0.99 
Sartel –AM 93.81±0.59 0.63 99.10±0.98 0.98 99.01±1.05 1.06 98.89±1.25 1.264
TABLE V - Results for accuracy for the proposed dissolution method
Analyte % level of recovery
Amount (mg)
Added Recovered %Recovery %RSD
TEL 80 32 31.56 98.62 1.10
100 40 38.82 97.05 0.89
120 48 47.52 99.0 1.24
AML 80 4 3.90 97.5 1.02
100 5 4.85 97.0 0.98
120 6 5.89 98.16 0.85
results obtained from validation show that the proposed 
dissolution method was scientifically sound. These 
advantages encourage the routine use of the developed 
dissolution method in the quality control analysis of TEL 
and AML in tablet dosage forms.
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